176 related articles for article (PubMed ID: 22251700)
1. Plasmacytoid dendritic cells lead the charge against tumors.
Jiménez-Baranda S; Silva IP; Bhardwaj N
J Clin Invest; 2012 Feb; 122(2):481-4. PubMed ID: 22251700
[TBL] [Abstract][Full Text] [Related]
2. Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells.
Drobits B; Holcmann M; Amberg N; Swiecki M; Grundtner R; Hammer M; Colonna M; Sibilia M
J Clin Invest; 2012 Feb; 122(2):575-85. PubMed ID: 22251703
[TBL] [Abstract][Full Text] [Related]
3. Disease-independent skin recruitment and activation of plasmacytoid predendritic cells following imiquimod treatment.
Urosevic M; Dummer R; Conrad C; Beyeler M; Laine E; Burg G; Gilliet M
J Natl Cancer Inst; 2005 Aug; 97(15):1143-53. PubMed ID: 16077073
[TBL] [Abstract][Full Text] [Related]
4. [New perspective in immunotherapy: local imiquimod treatment].
Kemény L; Nagy N
Orv Hetil; 2010 May; 151(19):774-83. PubMed ID: 20427260
[TBL] [Abstract][Full Text] [Related]
5. Topical imiquimod has therapeutic and immunomodulatory effects against intracranial tumors.
Xiong Z; Ohlfest JR
J Immunother; 2011 Apr; 34(3):264-9. PubMed ID: 21389872
[TBL] [Abstract][Full Text] [Related]
6. Increased number of mast cells in the dermis in actinic keratosis lesions effectively treated with imiquimod.
Oyama S; Funasaka Y; Tsuchiya SI; Kawana S; Saeki H
J Dermatol; 2017 Aug; 44(8):944-949. PubMed ID: 28342266
[TBL] [Abstract][Full Text] [Related]
7. Enhanced type I interferon signaling and recruitment of chemokine receptor CXCR3-expressing lymphocytes into the skin following treatment with the TLR7-agonist imiquimod.
Wenzel J; Uerlich M; Haller O; Bieber T; Tueting T
J Cutan Pathol; 2005 Apr; 32(4):257-62. PubMed ID: 15769273
[TBL] [Abstract][Full Text] [Related]
8. Plasmacytoid dendritic cell-derived type I interferon is crucial for the adjuvant activity of Toll-like receptor 7 agonists.
Rajagopal D; Paturel C; Morel Y; Uematsu S; Akira S; Diebold SS
Blood; 2010 Mar; 115(10):1949-57. PubMed ID: 20065291
[TBL] [Abstract][Full Text] [Related]
9. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice.
Ma F; Zhang J; Zhang J; Zhang C
Cell Mol Immunol; 2010 Sep; 7(5):381-8. PubMed ID: 20543857
[TBL] [Abstract][Full Text] [Related]
10. The TLR7 agonist imiquimod enhances the anti-melanoma effects of a recombinant Listeria monocytogenes vaccine.
Craft N; Bruhn KW; Nguyen BD; Prins R; Lin JW; Liau LM; Miller JF
J Immunol; 2005 Aug; 175(3):1983-90. PubMed ID: 16034143
[TBL] [Abstract][Full Text] [Related]
11. Imiquimod combined with dendritic cell vaccine decreases Treg proportion and enhances anti-tumor responses in mice bearing melanoma.
Ren S; Wang Q; Zhang Y; Lu C; Li P; Li Y
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2017 Feb; 33(2):145-50. PubMed ID: 29762000
[TBL] [Abstract][Full Text] [Related]
12. The TLR-7 agonist, imiquimod, enhances dendritic cell survival and promotes tumor antigen-specific T cell priming: relation to central nervous system antitumor immunity.
Prins RM; Craft N; Bruhn KW; Khan-Farooqi H; Koya RC; Stripecke R; Miller JF; Liau LM
J Immunol; 2006 Jan; 176(1):157-64. PubMed ID: 16365406
[TBL] [Abstract][Full Text] [Related]
13. 9-Phenanthrol enhances the generation of an CD8
Hartmann AK; Aranda Lopez P; Zajac M; Freichel M; Schild H; Radsak MP; Stassen M
J Dermatol Sci; 2017 Sep; 87(3):260-267. PubMed ID: 28823644
[TBL] [Abstract][Full Text] [Related]
14. Imiquimod.
Jobanputra KS; Rajpal AV; Nagpur NG
Indian J Dermatol Venereol Leprol; 2006; 72(6):466-9. PubMed ID: 17179631
[No Abstract] [Full Text] [Related]
15. Innovative uses of imiquimod.
Vender RB; Goldberg O
J Drugs Dermatol; 2005; 4(1):58-63. PubMed ID: 15696986
[TBL] [Abstract][Full Text] [Related]
16. TLR7 and TLR8 as targets in cancer therapy.
Schön MP; Schön M
Oncogene; 2008 Jan; 27(2):190-9. PubMed ID: 18176600
[TBL] [Abstract][Full Text] [Related]
17. Topical Imiquimod is an Effective and Safe Drug for Molluscum Contagiosum in Children.
Badavanis G; Pasmatzi E; Monastirli A; Georgiou S; Tsambaos D
Acta Dermatovenerol Croat; 2017 Jul; 25(2):164-166. PubMed ID: 28871935
[TBL] [Abstract][Full Text] [Related]
18. Imiquimod inhibits melanoma development by promoting pDC cytotoxic functions and impeding tumor vascularization.
Aspord C; Tramcourt L; Leloup C; Molens JP; Leccia MT; Charles J; Plumas J
J Invest Dermatol; 2014 Oct; 134(10):2551-2561. PubMed ID: 24751730
[TBL] [Abstract][Full Text] [Related]
19. Topical imiquimod in the treatment of metastatic melanoma to skin.
Wolf IH; Smolle J; Binder B; Cerroni L; Richtig E; Kerl H
Arch Dermatol; 2003 Mar; 139(3):273-6. PubMed ID: 12622616
[No Abstract] [Full Text] [Related]
20. Imiquimod: a topically applied link between innate and acquired immunity.
Hurwitz DJ; Pincus L; Kupper TS
Arch Dermatol; 2003 Oct; 139(10):1347-50. PubMed ID: 14568839
[No Abstract] [Full Text] [Related]
[Next] [New Search]